Dexmedetomidine in Reducing Incidence of Emergence Agitation After Nasal Surgery

• Status: Not yet recruiting
• Trial end date: 2023-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Various pharmacological interventions have been attempted previously to prevent postoperative EA with variable results. These include use of opioids (9), propofol (10), midazolam (11), ketamine (12), magnesium (13) and alpha-2 agonists like clonidine (14) and dexmedetomidine (15). Dexmedetomidine have been used with different dosages and different timings of administration with variable results and at the expense of major hemodynamic disturbances (16, 17, 18,). The objective of this study was to investigate the role of single dose of dexmedetomidine (0.5 mcg/kg) administered as 30 minutes infusion prior to extubation in reducing the incidence and severity of EA and coughing on extubation.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Security Forces Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• We will include patients aged 15 years to 65 years, ASA 1-3 who are planned to undergo general anesthesia for elective nasal surgeries in which nasal packing is used postoperatively

Exclusion Criteria:

• We will exclude patients with known allergy to study medications, BMI more than 35, history of obstructive sleep apnea, history of psychiatric illness, pregnancy and presence of liver and renal diseases.